{"id":959747,"date":"2026-05-07T08:20:42","date_gmt":"2026-05-07T12:20:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncologys-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression\/"},"modified":"2026-05-07T08:20:42","modified_gmt":"2026-05-07T12:20:42","slug":"alx-oncologys-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncologys-evorpacept-in-combination-with-zanidatamab-generates-promising-durable-response-in-patients-with-advanced-her2-positive-breast-cancer-and-high-cd47-expression\/","title":{"rendered":"ALX Oncology\u2019s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression"},"content":{"rendered":"
\n

\n
\n – Data from Phase 1b\/2 trial presented at ESMO Breast Cancer 2026 further validate a <\/em>
\n <\/strong>
\n
\n biomarker-driven development strategy for evorpacept –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – Findings are consistent with previous results from the randomized ASPEN-06 trial in HER2-positive gastric cancer, which indicated CD47 expression could potentially serve as an important predictive biomarker of evorpacept activity –<\/em>
\n <\/strong>\n <\/p>\n

\n
\n – ALX Oncology will host a webcast on May 8 to report first quarter 2026 financial results; breast cancer expert will discuss the evorpacept + zanidatamab trial results in detail –<\/em>
\n <\/strong>\n <\/p>\n

SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc. (\u201cALX Oncology\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced that data from exploratory analyses in the Phase 1b\/2 clinical trial evaluating the company\u2019s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals\u2019 zanidatamab (ZIIHERA\u00ae<\/sup>) in patients with heavily pre-treated HER2-positive metastatic breast cancer (mBC) were presented for the first time today in a poster session at the ESMO Breast Cancer 2026 congress<\/a>. The findings show that patients with centrally confirmed HER2-positive (ccHER2-positive) mBC and high CD47 expression experienced a promising, durable response.<\/p>\n

Specifically, patients in the trial with ccHER2-positive disease and high CD47 expression (defined as total membrane staining of ><\/u>20%) had a confirmed objective response rate (cORR) of 100% (n=5\/5), while the cORR was 25% (n=1\/4) among those with lower CD47 expression (<20%). Those patients whose tumors expressed higher levels of CD47 also had longer median progression-free survival (mPFS): 22.1 months as compared to 3.4 months in the low-CD47 expression group. The median duration of response (mDOR) among patients whose tumors expressed high levels of CD47 was also notable at 20.2 months.<\/p>\n

\u201cThere is a large and growing population of patients with advanced breast cancer who need novel treatment options once their disease has progressed following treatment with currently available therapies, including trastuzumab deruxtecan,\u201d said Funda Meric-Bernstam, M.D., Chair of the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, who presented the findings today. \u201cOur data suggest that adding evorpacept to HER2-targeted agents may provide one such option, and we may be able to optimize patient selection for these regimens by using a biomarker-driven approach that incorporates CD47.\u201d<\/p>\n

The Phase 1b\/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zanidatamab included patients with heavily pre-treated HER2-positive mBC (median of five prior HER2-targeted therapies), all of whom had received prior ENHERTU therapy. The primary trial results, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS),<\/a> demonstrated that the investigational combination generated promising anti-tumor activity and a manageable safety profile.<\/p>\n

The exploratory analyses comprised 24 patients, including 10 with ccHER2-positive disease. Seventeen of 24 samples were evaluable for CD47 expression, including samples from nine of the 10 ccHER2-positive patients. Patients received zanidatamab plus evorpacept at dosages of 20 mg\/kg (n=3) or 30 mg\/kg (n=21). As of the August 1, 2024 data cut-off, key findings from the analyses include:<\/p>\n